ArticleStem cell research & therapy2025
PARP inhibition augments immunomodulatory function of mesenchymal stem/stromal cells by promoting STAT1 phosphorylation.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HM568 Enhances NADMolecular neurobiology · 2026Article
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundMesenchymal stem/stromal cells (MSCs) have shown significant therapeutic effects in a range of autoimmune and hyperinflammatory diseases through their strong immunomodulatory properties, both in animal models and clinical settings. Exposure to inflammatory cytokines is crucial for MSCs to acquire immunoregulatory functions; however, the detailed mechanisms underlying this process remain largely unexplored.
methodMSCs with pharmacological inhibition or genetic knockout of poly ADP-ribose polymerase1 (PARP1) were treated with the inflammatory factors IFNγ and TNFα for 24 h. The mRNA and protein expression of chemokines and immunosuppressive molecules were detected by qRT-PCR and Western blotting, respectively. The therapeutic efficacy of MSCs was evaluated using a mouse concanavalin A-induced acute liver injury model and a dextran sulfate sodium-induced inflammatory bowel disease model. The phosphorylation of signal transducer and activator of transcription 1 (STAT1) was analyzed in activated MSCs, and STAT1 inhibition through either a STAT1 inhibitor or STAT1 knockout was employed to confirm the role of STAT1 in enhancing the immunoregulatory function of MSCs during PARP inhibition.
resultsPARP inhibition or genetic knockout of PARP1 further enhanced the immunoregulatory function of MSCs elicited by inflammatory cytokines IFNγ and TNFα, as evidenced by the upregulation of genes associated with immunoregulation in MSCs, augmentation of immunosuppressive functions of MSCs on T cells, and increased therapeutic effects of MSCs in mouse models of autoimmune and hyperinflammatory diseases. PARP inhibition was further shown to enhance the expression of immunosuppressive factors in primed MSCs through increased phosphorylation at the tyrosine 701 site on STAT1.
conclusionOur study indicates that like its pro-inflammatory role in macrophages, PARP also functions to undermine the immunosuppressive effects of MSCs, and PARP inhibition represents a strategy to further unleash the immunoregulatory power of MSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.